Navigation Links
First human study confirms that immune cells can be a primary cause of bone loss in gum disease

Researchers at The Forsyth Institute have confirmed in human gingival tissue that immune cells play a destructive role in periodontal disease. Although researchers had suspected the correlation between bone loss in periodontal (gum) disease and immune cells, this is the first time that this has been confirmed in human tissue samples. With this work, Forsyth scientists and colleagues hope to determine methods for intervening and halting bone loss and thus improving the health outcomes of the estimated 80 million Americans suffering from periodontal disease.

The study, led by Toshihisa Kawai, D.D.S., Ph.D., examined whether immune response to periodontal bacteria is protective or pathogenic in the context of gum disease. Periodontal disease is an infection of the teeth, and their supporting structures, which results in soft tissue and bone destruction, leading to tooth loss. Dr. Kawai and his colleagues had found that B cells (B and T lymphocytes are immune cells) can contribute to increased periodontal bone loss coordinating with activated T-cells. Both cell types had previously been found to manifest a host immune response to the bacteria causing bone loss in animal models, by his group.

"This research validates our hypothesis that immune cells are harmful in gum disease," said Dr. Kawai. "It's a groundbreaking discovery because it truly gives a new understanding of periodontal disease, while also raising interesting questions about immune cells. We hope this work will help us save people's teeth in the future."

Research Overview
RANKL is a protein that is a major factor in the regulation of osteoclasts (cells that destroy bone). Dr. Kawai's research examined the receptor activator of NF-kB ligand, (RANKL)-mediated osteoclastogeneis, and the pivotal role it plays in inflammatory bone resorption. The aim of this study, which will be published in the September issue of the American Journal of Pathology, was to identify the cellular s ource of RANKL in the bone resorptive lesions of periodontal disease. An active periodontal lesion is characterized by the prominent infiltration of B cells and T cells, both of which are major immune lymphocytes. Specifically, the occupancy of 50-60% of such cellular infiltrates by plasma cells (ultimately, differentiated B cells) makes periodontal disease very distinct from other chronic infectious diseases. B cells are known to produce a weapon (antibody) that normally attacks bacteria and protects our body from bacterial infection. As a consequence of dense infiltration of B cells found in the gum, periodontally diseased patients mount significantly elevated antibody levels to bacteria colonizing around gum tissues. However, the fact that periodontal disease continues to progress, even though B cells produce a weapon to fight off the bacteria, raised an important and interesting question. To answer this question, Dr. Kawai's group found that RANKL expressed on the T and B cells in the patient's gingival tissues were functionally sufficiently potent to induce bone destructive cells (osteoclasts) in a laboratory culture system, in spite of the elevated presence of B and T lymphocytes. Since it has never been reported that any bacteria per se invade and resorb bone independent of osteoclast activation, RANKL expression by T cells and B cells proves to be one of the major stimuli of osteoclast precursor cells and, hence, bone loss through periodontal disease.


'"/>

Source:Forsyth Institute


Related biology news :

1. Timing is everything: First step in protein building revealed
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
5. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
6. First real-time view of developing neurons reveals surprises, say Stanford researchers
7. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
8. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
9. First frozen egg baby born in Canada
10. Human Cells Filmed Instantly Messaging for First Time
11. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
Breaking Biology Technology: